Cerebrolysin in Alzheimer's disease: A randomized, double-blind, placebo-controlled trial with a neurotrophic agent

Journal of Neural Transmission

Volumn 109, Issue 7-8, 2002, Pages 1089-1104

  Panisset, M ^a   Gauthier, S ^a   Moessler, H ^b   Windisch, M ^c  

^a MCGILL UNIVERSITY   (Canada)

^b EBEWE Arzneimittel GmbH   (Austria)

^c JSW Life Sciences GmbH   (Austria)

Author keywords

Alzheimer's disease; Cerebrolysin; Neurodegeneration; Neurotrophic factors; Peptide derivative

Indexed keywords

CEREBROLYSIN; PLACEBO;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ANXIETY; ARTICLE; ASTHENIA; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HEADACHE; HUMAN; HYPERVENTILATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NAUSEA; ONSET AGE; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VERTIGO; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMINO ACIDS; APOLIPOPROTEINS E; COGNITION; DEPRESSION; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PHENOTYPE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 0036318340     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020200092     Document Type: Article

References (48)

1. Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain
2. Cornell scale for depression in dementia
3. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease
4. Neurotrophic factor therapy of Alzheimer's disease
5. In vivo upregulation of the blood-brain barrier GLUT-1 glucose transporter by brain-derived peptides
6. NGF and cholinergic control of behavior: Anticipation and enhancement of scopolamine effects in neonatal mice
7. Lesions of the nucleus basalis magnocellularis in the rat: Morphological, biochemical and behavioral reparative effect of nerve growth factor and ganglioside gm1
8. Nerve growth factor attenuates cholinergic deficits following traumatic brain injury in rats
9. NGF improves spatial memory in aged rodents as a function of age
10. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician
11. Nerve growth factor and nootropic drug Cere but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: Short-term study
12. The effects of nerve growth factor on spatial recent memory in aged rats persist after discontinuation of treatment
13. Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease
14. Development of a functional measure for persons with Alzheimer's disease: The disability assessment of dementia
15. Stabilization approaches to Alzheimer's disease
16. The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats
17. Ameliorative influence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion
18. Nerve growth factor (NGF) reverses axotomy-induced decreases in choline acetyltransferase, NGF receptor and size of medial septum cholinergic neurons
19. Nerve growth factor and choline acetyltransferase activity levels in the rat brain following experimental impairment of cerebral glucose and energy metabolism
20. A new scale for the staging of dementia
21. The five-five, ten-ten year plan for Alzheimer's disease
22. A multidimensional approach in testing nootropic drug effects (Cerebrolysin)
23. Die brauchbarkeit der ereigniskorrelierten negativität zum nachweis therapeutischer wirkungen von nootropika am beispiel von Cerebrolysin
24. Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the rat
25. Effect of recombinant human nerve growth factor on presynaptic cholinergic function in rat hippocampal slices following partial septohippocampal lesions: Measures of [3H]acetylcholine synthesis, [3H]acetylcholine release and choline acetyltransferase
26. Assessment of older people: Self-maintening and instrumental activities of daily living
27. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease
28. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice
29. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease
30. Long-term effects of nerve growth factor and neural transplants on behavior of rats with medial septal lesions
31. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats
32. Behavioural symptoms in Alzheimer's disease: Phenomenology and treatment
33. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
34. Pathological verification of ischemia score in differentiation of dementias
35. A new rating scale for Alzheimer's disease
36. Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT)
37. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy
38. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease
39. Global assessment measures in dementia
40. Morphological observation of effects of Cere on cultured neural cells
41. Neurotrophic-like effects of FPF-1070 on cultured neurons from chick embryonic dorsal root ganglia
42. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy
43. Rescue of basal forebrain cholinergic neurons after implantation of genetically modified cells producing recombinant NGF
44. Potential use of neurotrophic agents in the treatment of neurodegenerative disorders
45. Can Cerebrolysin influence chronic deterioration of spatial learning and memory?
46. Hypophagia is induced by intracerebroventricular administration of nerve growth factor
47. Exogenous NGF affects cholinergic transmitter function and Y-maze behavior in aged Fischer 344 male rats
48. Efficacy of FPF 1070 (Cerebrolysin) in patients with Alzheimer's disease: A multicentre, randomised, double-blind, placebo-controlled trial